Regenxbio Historical Income Statement

RGNX Stock

USD 10.01 0.46 4.82%

Historical analysis of Regenxbio income statement accounts such as Gross Profit of 91.4 M, Other Operating Expenses of 184 M, Research Development of 243.9 M or Cost Of Revenue of 20.3 M can show how well Regenxbio performed in making a profits. Evaluating Regenxbio income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Regenxbio's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Regenxbio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Regenxbio is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regenxbio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.

About Regenxbio Income Statement Analysis

Regenxbio Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Regenxbio shareholders. The income statement also shows Regenxbio investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Regenxbio Income Statement Chart

At this time, Regenxbio's Depreciation And Amortization is fairly stable compared to the past year. Total Revenue is likely to rise to about 111.6 M in 2024, whereas Interest Expense is likely to drop slightly above 6.5 M in 2024.

Selling General Administrative Total Revenue Gross Profit Other Operating Expenses

Total Revenue

Total revenue comprises all receipts Regenxbio generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Regenxbio minus its cost of goods sold. It is profit before Regenxbio operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Regenxbio. It is also known as Regenxbio overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Regenxbio's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Regenxbio current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regenxbio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.At this time, Regenxbio's Depreciation And Amortization is fairly stable compared to the past year. Total Revenue is likely to rise to about 111.6 M in 2024, whereas Interest Expense is likely to drop slightly above 6.5 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	418.5M	58.2M	53.0M	91.4M
Total Revenue	470.3M	112.7M	90.2M	111.6M

Gross Profit Total Revenue

Regenxbio income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Interest Income	Extraordinary Items	Tax Provision	Non Operating Income Net Other	Reconciled Depreciation
Depreciation And Amortization		-0.79	0.24	0.29	0.25	0.28	-0.12	-0.1	0.33	0.02	0.42	0.25	-0.22	-0.8	-0.23	0.34	-0.23	-0.16	-0.4	0.35	-0.69	0.33
Interest Expense	-0.79		0.35	0.12	0.1	0.32	-0.2	-0.21	0.29	-0.31	0.17	0.34	-0.12	0.68	-0.12	-0.14	-0.12	0.07	0.07	-0.12	0.89	0.26
Selling General Administrative	0.24	0.35		0.64	0.55	1.0	-0.47	-0.46	0.94	-0.43	0.92	1.0	-0.48	-0.04	-0.5	0.35	-0.5	0.12	-0.31	0.41	0.38	0.92
Total Revenue	0.29	0.12	0.64		0.99	0.62	0.31	0.33	0.55	0.36	0.72	0.6	0.29	-0.31	0.26	0.9	0.26	0.28	-0.06	0.88	0.14	0.45
Gross Profit	0.25	0.1	0.55	0.99		0.53	0.41	0.42	0.46	0.45	0.63	0.51	0.38	-0.29	0.36	0.92	0.36	0.32	-0.04	0.89	0.13	0.35
Other Operating Expenses	0.28	0.32	1.0	0.62	0.53		-0.49	-0.48	0.94	-0.44	0.95	1.0	-0.51	-0.08	-0.53	0.35	-0.53	0.09	-0.3	0.4	0.34	0.93
Operating Income	-0.12	-0.2	-0.47	0.31	0.41	-0.49		1.0	-0.62	0.99	-0.32	-0.51	0.99	-0.23	0.99	0.58	0.99	0.24	0.59	0.5	-0.29	-0.64
Ebit	-0.1	-0.21	-0.46	0.33	0.42	-0.48	1.0		-0.61	0.99	-0.3	-0.5	0.99	-0.23	0.99	0.6	0.99	0.23	0.58	0.51	-0.3	-0.63
Research Development	0.33	0.29	0.94	0.55	0.46	0.94	-0.62	-0.61		-0.57	0.87	0.94	-0.64	-0.04	-0.65	0.22	-0.65	0.03	-0.58	0.28	0.39	0.92
Ebitda	0.02	-0.31	-0.43	0.36	0.45	-0.44	0.99	0.99	-0.57		-0.25	-0.47	0.97	-0.34	0.96	0.64	0.96	0.21	0.53	0.56	-0.39	-0.59
Cost Of Revenue	0.42	0.17	0.92	0.72	0.63	0.95	-0.32	-0.3	0.87	-0.25		0.93	-0.37	-0.33	-0.39	0.52	-0.39	-0.03	-0.21	0.53	0.14	0.86
Total Operating Expenses	0.25	0.34	1.0	0.6	0.51	1.0	-0.51	-0.5	0.94	-0.47	0.93		-0.52	-0.04	-0.54	0.31	-0.54	0.11	-0.31	0.37	0.37	0.93
Income Before Tax	-0.22	-0.12	-0.48	0.29	0.38	-0.51	0.99	0.99	-0.64	0.97	-0.37	-0.52		-0.1	1.0	0.54	1.0	0.3	0.59	0.46	-0.19	-0.66
Total Other Income Expense Net	-0.8	0.68	-0.04	-0.31	-0.29	-0.08	-0.23	-0.23	-0.04	-0.34	-0.33	-0.04	-0.1		-0.09	-0.44	-0.09	0.36	-0.01	-0.4	0.83	-0.07
Net Income	-0.23	-0.12	-0.5	0.26	0.36	-0.53	0.99	0.99	-0.65	0.96	-0.39	-0.54	1.0	-0.09		0.51	1.0	0.3	0.6	0.43	-0.19	-0.67
Income Tax Expense	0.34	-0.14	0.35	0.9	0.92	0.35	0.58	0.6	0.22	0.64	0.52	0.31	0.54	-0.44	0.51		0.51	0.21	0.17	0.96	-0.16	0.15
Net Income From Continuing Ops	-0.23	-0.12	-0.5	0.26	0.36	-0.53	0.99	0.99	-0.65	0.96	-0.39	-0.54	1.0	-0.09	1.0	0.51		0.3	0.6	0.43	-0.19	-0.67
Interest Income	-0.16	0.07	0.12	0.28	0.32	0.09	0.24	0.23	0.03	0.21	-0.03	0.11	0.3	0.36	0.3	0.21	0.3		0.22	0.28	0.37	-0.12
Extraordinary Items	-0.4	0.07	-0.31	-0.06	-0.04	-0.3	0.59	0.58	-0.58	0.53	-0.21	-0.31	0.59	-0.01	0.6	0.17	0.6	0.22		0.14	-0.15	-0.51
Tax Provision	0.35	-0.12	0.41	0.88	0.89	0.4	0.5	0.51	0.28	0.56	0.53	0.37	0.46	-0.4	0.43	0.96	0.43	0.28	0.14		-0.13	0.17
Non Operating Income Net Other	-0.69	0.89	0.38	0.14	0.13	0.34	-0.29	-0.3	0.39	-0.39	0.14	0.37	-0.19	0.83	-0.19	-0.16	-0.19	0.37	-0.15	-0.13		0.29
Reconciled Depreciation	0.33	0.26	0.92	0.45	0.35	0.93	-0.64	-0.63	0.92	-0.59	0.86	0.93	-0.66	-0.07	-0.67	0.15	-0.67	-0.12	-0.51	0.17	0.29

Click cells to compare fundamentals

Regenxbio Account Relationship Matchups

Regenxbio income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	(48.6M)	8.4M	9.6M	12.9M	17.3M	18.2M
Interest Expense	107.2M	771K	26.3M	23.3M	6.9M	6.5M
Selling General Administrative	51.8M	63.8M	79.3M	85.3M	88.5M	47.8M
Total Revenue	35.2M	154.6M	470.3M	112.7M	90.2M	111.6M
Gross Profit	27.0M	118.9M	418.5M	58.2M	53.0M	91.4M
Other Operating Expenses	184.2M	273.8M	310.4M	375.6M	358.4M	184.0M
Operating Income	(149.0M)	(119.2M)	160.0M	(262.9M)	(268.1M)	(254.7M)
Ebit	(149.0M)	(105.2M)	160.0M	(257.2M)	(256.8M)	(243.9M)
Research Development	124.2M	166.3M	181.4M	242.5M	232.3M	243.9M
Ebitda	(197.6M)	(96.8M)	169.5M	(244.2M)	(239.5M)	(227.5M)
Cost Of Revenue	8.2M	35.7M	51.8M	54.5M	37.2M	20.3M
Total Operating Expenses	176.0M	238.1M	258.5M	321.1M	321.2M	163.8M
Income Before Tax	(97.5M)	(106.0M)	141.2M	(280.4M)	(263.6M)	(250.5M)
Total Other Income Expense Net	51.5M	13.2M	(18.7M)	(17.5M)	4.5M	3.3M
Net Income	(94.7M)	(111.3M)	127.8M	(280.3M)	(263.5M)	(250.3M)
Income Tax Expense	(2.8M)	5.2M	13.4M	(84K)	(152K)	(144.4K)
Net Income From Continuing Ops	(94.7M)	(111.3M)	127.8M	(280.3M)	(260.5M)	(247.5M)
Net Income Applicable To Common Shares	(94.7M)	(111.3M)	127.8M	(280.3M)	(252.3M)	(239.7M)
Interest Income	3.0M	4.3M	719K	342K	243K	230.9K
Tax Provision	(2.8M)	5.2M	13.4M	(84K)	(43K)	(40.9K)
Net Interest Income	3.0M	3.5M	(25.6M)	(22.9M)	(9.6M)	(10.0M)
Non Operating Income Net Other	16.0M	51.5M	14.0M	7.5M	8.7M	17.2M
Reconciled Depreciation	7.2M	8.4M	9.6M	12.9M	17.1M	9.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Regenxbio Stock Analysis

When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regenxbio Historical Income Statement

About Regenxbio Income Statement Analysis

Regenxbio Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Regenxbio income statement Correlations

Regenxbio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regenxbio income statement Accounts

Also Currently Popular

Additional Tools for Regenxbio Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Net Income	+ 1.0	Income Before Tax
Net Income From Continuing Ops	+ 1.0	Income Before Tax

Total Other Income Expense Net	- 0.8	Depreciation And Amortization
Interest Expense	- 0.79	Depreciation And Amortization
Non Operating Income Net Other	- 0.69	Depreciation And Amortization
Reconciled Depreciation	- 0.67	Net Income From Continuing Ops
Reconciled Depreciation	- 0.67	Net Income
Reconciled Depreciation	- 0.66	Income Before Tax